Overview
Gastritis complicated by sepsis involves inflammation of the gastric mucosa alongside systemic inflammatory response syndrome, often seen in patients with underlying liver disease, leading to significant morbidity and mortality 1.Diagnosis
Assess clinical signs of sepsis (e.g., fever, tachycardia, hypotension) 1.
Evaluate laboratory markers including inflammatory cytokines (IL-6, TNF-α) and lipid profiles (HDL, APO A-I) 1.
Consider imaging or endoscopy to confirm gastritis and assess severity 1.Management
Initiate broad-spectrum antibiotics tailored to suspected infection source 1.
Optimize hemodynamic support with vasopressors as needed, monitoring mean arterial pressure 1.
Manage underlying liver disease aggressively, considering potential hepatoprotective therapies 1.
Monitor and manage electrolyte imbalances and renal function closely 1.Special Populations
Cirrhosis: Lower APO A-I levels correlate with poorer outcomes; monitor APO A-I <47.5 mg/dl for risk stratification 1.Key Recommendations
Monitor serum APO A-I levels in cirrhotic patients with severe sepsis to predict 90-day mortality (Evidence: Moderate) 1.
Implement early goal-directed therapy focusing on hemodynamic stabilization and inflammatory markers (Evidence: Moderate) 1.
Tailor antibiotic therapy based on clinical suspicion and local resistance patterns (Evidence: Expert opinion) 1.References
1 Tsai MH, Peng YS, Chen YC, Lien JM, Tian YC, Fang JT et al.. Low serum concentration of apolipoprotein A-I is an indicator of poor prognosis in cirrhotic patients with severe sepsis. Journal of hepatology 2009. link